Loading viewer...
investor_presentation
Format: PDF investor_presentation
Inmunology presents its XPro and INKmune immunology platforms designed to repair innate immune dysfunction across multiple indications. The June 2024 presentation outlines clinical milestones including Phase 2 trials in atopic dermatitis, treatment-resistant depression, and metastatic castration-resistant prostate cancer, with key data readouts expected through 2025.
investor_presentation
30 Pages
Elevation Gold Mining